Oppenheimer analyst Andreas Argyrides initiated coverage of Regulus with an Outperform rating and $7 price target. The analyst says Regulus is set to advance its next-generation anti-miR17 oligonucleotide, RGLS8429, into a pivotal trial for the treatment of autosomal dominant polycystic kidney disease. RGLS8429 offers the prospect of disease modification and is positioned as the preferred treatment for high-risk ADPKD patients, the analyst tells investors in a research note. The firm sees a clear path toward accelerated approval that could lead to approval in the second half of 2028.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue